Case Study: Nektar Therapeutics achieves faster, more robust bioprocess development with Culture Biosciences

Nektar Therapeutics scales bioprocess development with Culture Biosciences’ bioreactor runs

Nektar Therapeutics, a biopharmaceutical company specializing in PEG-modified therapeutics, faced significant challenges in bioprocess development due to the unique complexity of its drug manufacturing. Each new therapeutic program required starting from scratch, demanding immense flexibility and bioreactor capacity to screen numerous parameters and ensure process robustness. The company needed to move quickly while managing resources across multiple programs, all without being constrained by the limited availability of internal equipment.

Culture Biosciences provided a solution through its guaranteed capacity subscription and cloud-based bioreactor platform. This service gave Nektar flexible access to numerous bioreactor runs, enabling them to conduct extensive Design of Experiments (DoE) studies, including their largest parallel reactor study to date. The results were a solid foundation of data that eliminated guesswork, proven process robustness for tech transfer to CMOs, and the ability to make confident, data-driven decisions. This partnership with Culture Biosciences allowed Nektar to accelerate development, mitigate risks effectively, and advance their pipeline of life-saving therapies with greater speed and confidence.

Nektar Therapeutics